About Delos Capital
Delos Capital is a private equity firm founded in 2013. It is primarily based in New York City, United States. As of Oct 2026, Delos Capital is an active investor with a portfolio of 23 companies, comprising 23 funding rounds and 9 acquisitions. In the last 12 months, it has participated in 1 funding round. The firm primarily invests in companies based in United States and China. Its portfolio is spread across a wide range of sectors from Life Sciences to Enterprise Applications. Its latest investment was a $***** Series B round in Rejoni on Jun 16, 2026 which also saw participation from Clavystbio, AMED Ventures and other investors.
Overall Delos Capital portfolio has seen 1 IPO and 5 acquisitions, namely Clover Biopharma, HOP Energy and Exela. A lot of funds co-invest with Delos Capital, with names like Orbimed sharing a substantial percentage of its portfolio.
Delos Capital has a team of 9 people, including 3 partners.
Key Metrics
Founded Year
2013
Location
New York City, United States
Portfolio Companies
Portfolio Sectors
Portfolio Locations
Acquisition Deals
Investment Deals
Delos Capital's Portfolio
Delos Capital has a portfolio of 23 companies. They have invested in a total of 23 companies. Their most recent investment was in Rejoni (Series B round) on Jun 16, 2026. Here are the most recent investments by Delos Capital:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Jun 16, 2026 | Series B | 7833 | and 6 others | |
Aug 22, 2025 | Series B | 4491 | ||
Oct 23, 2024 | Series C | 1720 | ||
Apr 08, 2024 | Series A | 4814 |
Delos Capital has acquired 9 companies. Their most recent acquisition was of Le Sueur on Jan 05, 2023. Here are the most recent acquisitions by Delos Capital:
Acquisition Date | Company | Short Description | Total Funding | Founded Year |
|---|---|---|---|---|
Jan 05, 2023 | Provider of aluminum casting and thermoplastic injection molding solution | - | 1946 | |
May 02, 2024 | Provider of dry waste recycling services | - | 2014 | |
Jul 31, 2018 | Energy services provider for design and installation of HVAC systems | - | 2009 | |
Jun 04, 2018 | Chain of fitness clubs | - | 2014 |
Here is the portfolio snapshot of Delos Capital:
Investments by Year
The maximum number of investments were made in 2024
Acquisitions by Year
The maximum number of acquisitions were made in 2018
Portfolio by Location
Companies are primarily in United States and China
Portfolio by Sector
Companies are primarily in Life Sciences
Team profile of Delos Capital
Delos Capital has a team of 9 members including 3 Partners and 2 Principals located in United States, Australia and 1 more location. Delos Capital's team does not sit on the board of any company as of now.Here is a list of all team members in Delos Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Sydney | - | - | |
Partner | Alkmaar | - | - | |
Partner | New York | - | ||
Principal | New York City | - | ||
Principal | New York City | - | ||
Associate | New York City | - | - | |
Associate | New York | - |
Co-investors of Delos Capital
Over the past 13 years, 65 investors have co-invested in Delos Capital's portfolio companies.
- Top Co-investors of Delos Capital: 65 investors entered a company along with Delos Capital. These include investors like Orbimed (2 companies).
Delos Capital News
•
Rejoni, Inc. Secures $25 Million in Financing for Juveena® Hydrogel SystemThe Joplin Globe•Jun 16, 2026•Rejoni, Iyengar Capital Partners, Clavystbio, AMED Ventures and 5 others
•
TRex Bio Raises $50M to Advance Eczema Drug TestingBioPharmaDive•Jan 27, 2026•TRexBio, Affinity Asset Advisors, Avego, Johnson & Johnson Innovation and 8 others
•
STRM.BIO Raises $8M in Series Seed 2 FinancingMassinvestor•Jan 07, 2026•STRM.BIO, Recordati, Delos Capital, Boehringer Ingelheim Venture Fund and 3 others
•
Avenzo Therapeutics Announces $60 Million Series B FinancingBusiness Wire•Sep 22, 2025•Avenzo Therapeutics, LAV, Deep Track Capital, INCE Capital and 12 others
•
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Developmentintelligence360•Nov 21, 2024•TRexBio, Delos Capital Partners, Delos Capital, Avego and 7 others
•
Avenzo Therapeutics Provides Corporate Update and Announces Closing of Series A/A-1 FinancingBusiness Wire•Nov 18, 2024•Avenzo Therapeutics, VelaVigo, Orbimed, Foresite Capital and 13 others
•
TRex Bio raises $84M to compete in crowded immune drug fieldBioPharmaDive•Nov 13, 2024•TRexBio, Delos Capital, Polaris Partners, Johnson & Johnson and 6 others
•
Radiopharma biotech Alpha-9 Oncology closes $175M Series C fundraiseEndPoints News•Oct 23, 2024•Alpha-9 Oncology, Janus Henderson Investors, Delos Capital, Digitalis Ventures and 12 others
•
•
Cardurion closes $260m in Series B to develop cardiovascular pipelinePharmaceutical Technology•Jul 17, 2024•Cardurion, Bain Capital, Ascenta Capital, New Enterprise Associates and 10 others
